DongKook Life Science

303810 · KOSDAQ · ₩303810 · 동국생명과학

₩2,275▼ ₩5 (0.22%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩3,830

vs the current price (₩2,275)

Enterprise value
₩117B
Equity value
₩123B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 68% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩2,275, the model needs an operating margin of 5.9% every year (it uses 9.2%).
  • Or revenue growth −23.2 points a year higher than assumed in each of the 5 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩2,338
+2.8%
Base
₩3,830
+68.4%
Bull
₩6,451
+183.6%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (9.2%).

Revenue growth

  • -1.1%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-1.1% a year, annual reports), fading to 3% by year 5.

  • -0.1%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-1.1% a year, annual reports), fading to 3% by year 5.

  • 0.9%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-1.1% a year, annual reports), fading to 3% by year 5.

  • 2%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-1.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-1.1% a year, annual reports), fading to 3% by year 5.

Business

  • 9.2%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3.3%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 4.1%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).

  • 40%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 88 weeks of weekly returns against KOSPI (official index); raw beta 0.13, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩118B
Net debt (borrowings and leases − cash and deposits)
−₩5.7B
+ Stakes and investments
₩2M
Associates, long-term financial assets and deposits (book value)
Shares
31,984,140
Share price
₩2,275
Market cap
₩73B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩132B₩130B₩116B₩116B₩117B₩120B₩123B
Growth—−1.1%−1.1%−0.1%0.9%2.0%3.0%
EBIT₩12B₩13B₩11B₩11B₩11B₩11B₩11B
EBIT margin9.0%10.0%9.2%9.2%9.2%9.2%9.2%
After-tax EBIT₩8.6B₩9.5B₩7.8B₩7.8B₩7.8B₩8B₩8.2B
+ Depreciation——₩3.8B₩3.8B₩3.9B₩4B₩4.1B
− Capital spending₩5.1B₩5.7B₩4.8B₩4.8B₩4.8B₩4.9B₩5.1B
− Working capital—₩18B−₩518M−₩47M₩419M₩939M₩1.4B
Free cash flow——₩7.4B₩6.9B₩6.5B₩6.1B₩5.8B
Discount factor——0.9310.8670.8070.7510.700
Present value——₩6.8B₩6B₩5.2B₩4.6B₩4.1B

Terminal value ₩129B, worth ₩90B today: 77% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩4,169₩4,389₩4,657₩4,992₩5,424
6.9%₩3,826₩3,997₩4,202₩4,451₩4,763
7.4%₩3,537₩3,672₩3,830₩4,020₩4,252
7.9%₩3,290₩3,398₩3,522₩3,669₩3,844
8.4%₩3,077₩3,163₩3,262₩3,377₩3,512

Now (TTM)

Market cap
₩73B
Enterprise value
₩67B
P/E
14.8×
P/B
0.5×
P/S
0.6×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

2025
Price₩3,660
Market cap₩117B
P/E13.5×
P/B0.9×
P/S0.9×
EV/EBITDA—
Dividend yield0.0%

Loading data for this company — check back soon

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
DongKook Life Science14.8×0.5×0.6×—0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: DongKook Life Science / 동국생명과학 / 303810 / KRX:303810

Source: KRX statistical information